211 related articles for article (PubMed ID: 8312859)
1. Inhibitory effects of S-(1,2-dicarboxyethyl)glutathione on collagen-induced platelet aggregation; enhancements of cyclic AMP level and adenylate cyclase activity in platelets by S-(1,2-dicarboxyethyl)glutathione.
Tsuboi S; Fujiwara E; Ogata K; Sakaue A; Nakayama T; Ohmori S
Biol Pharm Bull; 1993 Nov; 16(11):1083-6. PubMed ID: 8312859
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
Haslam RJ; Davidson MM; Desjardins JV
Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of platelet aggregation by S-(1,2-dicarboxyethyl)glutathione, intrinsic tripeptide in liver, heart, and lens.
Tsuboi S; Ohnaka M; Ohmori S; Sakaue T; Ogata K; Itano T; Hatase O
Arch Biochem Biophys; 1990 May; 279(1):146-50. PubMed ID: 2110801
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
5. YC-1, a novel activator of platelet guanylate cyclase.
Ko FN; Wu CC; Kuo SC; Lee FY; Teng CM
Blood; 1994 Dec; 84(12):4226-33. PubMed ID: 7527671
[TBL] [Abstract][Full Text] [Related]
6. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
7. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
8. Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets.
Yu SM; Chen CC; Ko FN; Huang YL; Huang TF; Teng CM
Biochem Pharmacol; 1992 Jan; 43(2):323-9. PubMed ID: 1310852
[TBL] [Abstract][Full Text] [Related]
9. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human platelet adenylate cyclase by collagen fibres. Effect of collagen is additive with that of adrenaline, but interactive with that of thrombin.
Farndale RW; Winkler AB; Martin BR; Barnes MJ
Biochem J; 1992 Feb; 282 ( Pt 1)(Pt 1):25-32. PubMed ID: 1311555
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP-independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets.
Tsikas D; Ikic M; Tewes KS; Raida M; Frölich JC
FEBS Lett; 1999 Jan; 442(2-3):162-6. PubMed ID: 9928994
[TBL] [Abstract][Full Text] [Related]
12. Interrelation of platelet aggregation, release reaction and thromboxane A2 production.
Balduini CL; Bertolino G; Noris P; Sinigaglia F; Bisio A; Torti M
Biochem Biophys Res Commun; 1988 Oct; 156(2):823-9. PubMed ID: 3190682
[TBL] [Abstract][Full Text] [Related]
13. High concentrations of exogenous arachidonate inhibit calcium mobilization in platelets by stimulation of adenylate cyclase.
Kowalska MA; Rao AK; Disa J
Biochem J; 1988 Jul; 253(1):255-62. PubMed ID: 2458717
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
16. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory mechanisms of metallothionein on platelet aggregation in in vitro and platelet plug formation in in vivo experiments.
Sheu JR; Hsiao G; Shen MY; Wang Y; Lin KH; Lin CH; Chou DS
Exp Biol Med (Maywood); 2003 Dec; 228(11):1321-8. PubMed ID: 14681547
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
19. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet aggregation by chlorogenic acid via cAMP and cGMP-dependent manner.
Cho HJ; Kang HJ; Kim YJ; Lee DH; Kwon HW; Kim YY; Park HJ
Blood Coagul Fibrinolysis; 2012 Oct; 23(7):629-35. PubMed ID: 22885765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
